Education
About Us
Working with TipRanks
Follow Us
Silo Pharma (SILO)
NASDAQ:SILO
SILO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.41 - $3.37
Previous CloseN/A
Volume152.45M
Average Volume (3M)598.88K
Market Cap
$6.06M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.35
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding9,401,128
10 Day Avg. Volume373,256
30 Day Avg. Volume598,880
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Silo Pharma News
SILO FAQ
What was Silo Pharma’s price range in the past 12 months?
Silo Pharma lowest stock price was $0.41 and its highest was $3.37 in the past 12 months.
What is Silo Pharma’s market cap?
Silo Pharma’s market cap is $6.06M.
When is Silo Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Silo Pharma’s earnings last quarter?
Currently, no data Available
Is Silo Pharma overvalued?
According to Wall Street analysts Silo Pharma’s price is currently Overvalued.
Does Silo Pharma pay dividends?
Silo Pharma does not currently pay dividends.
What is Silo Pharma’s EPS estimate?
Silo Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Silo Pharma have?
Silo Pharma has 9,401,128 shares outstanding.
What happened to Silo Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Silo Pharma?
Currently, no hedge funds are holding shares in SILO
Company Description
Silo Pharma
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
Silo Pharma (SILO) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
―
Creative Medical Technology Holdings
―
Alzamend Neuro
―
Longevity Health Holdings
―
Klotho Neurosciences
―
Ownership Overview
2.82% Insiders
0.76% Mutual Funds
3.68% Other Institutional Investors
89.06% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---